ResearcherKarolinska University HospitalActive in the last 2 years
Maria Gustafsson Liljefors
Matched on ORCID iD 0009-0009-6683-8424; OpenAlex author ID A5103754242. Sources: OpenAlex.
Their work
- Papers
- 5 (first author 0, last author 1)
- Trials
- 0
- Grants
- 0
- Labs led
- 0
- Collaborators
- 22
2019: 1 paper · 2020: none · 2021: 1 paper · 2022: none · 2023: none · 2024: 1 paper · 2025: 1 paper · 2026: 1 paper
Papers 5
- Association between pancreatic enzyme replacement therapy and mortality in pancreatic cancer: a matched case-control study. Co-author DOI 10.1016/j.pan.2025.12.008↗
- Prospective evaluation of surgical treatment of liver metastasizing pancreatic cancer - ScanPan study protocol. Co-author DOI 10.1186/s12893-025-02983-w↗
- Consistency of a clinical decision support system with molecular tumour board recommendations for tumour sequencing-guided treatment of pancreatic cancer. Co-author DOI 10.1016/j.esmogo.2024.100070↗
- Discordant Reporting of a Previously Undescribed Pathogenic Germline BRCA2 Variant in Blood and Tumor Tissue in a Patient With Pancreatic Adenocarcinoma. Last author DOI 10.1200/po.21.00024↗
- Survival Benefits of Chemotherapy for Patients with Advanced Pancreatic Cancer in A Clinical Real-World Cohort. Co-author DOI 10.3390/cancers11091326↗
Closest collaborators
The 22 strongest of 22 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.
- Matthias J. Löhr · 4 shared papers, 2019–2026 · strength 0.75
- Paper Association between pancreatic enzyme replacement therapy and mortality in pancreatic cancer: a matched case-control st… DOI 10.1016/j.pan.2025.12.008↗
- Paper Consistency of a clinical decision support system with molecular tumour board recommendations for tumour sequencing-gui… DOI 10.1016/j.esmogo.2024.100070↗
- Paper Discordant Reporting of a Previously Undescribed Pathogenic Germline BRCA2 Variant in Blood and Tumor Tissue in a Patie… DOI 10.1200/po.21.00024↗
- Poya Ghorbani · 3 shared papers, 2024–2026 · strength 0.68
- Paper Association between pancreatic enzyme replacement therapy and mortality in pancreatic cancer: a matched case-control st… DOI 10.1016/j.pan.2025.12.008↗
- Paper Prospective evaluation of surgical treatment of liver metastasizing pancreatic cancer - ScanPan study protocol. DOI 10.1186/s12893-025-02983-w↗
- Paper Consistency of a clinical decision support system with molecular tumour board recommendations for tumour sequencing-gui… DOI 10.1016/j.esmogo.2024.100070↗
- Maximilian Kordes · 3 shared papers, 2019–2024 · strength 0.46
- Paper Consistency of a clinical decision support system with molecular tumour board recommendations for tumour sequencing-gui… DOI 10.1016/j.esmogo.2024.100070↗
- Paper Discordant Reporting of a Previously Undescribed Pathogenic Germline BRCA2 Variant in Blood and Tumor Tissue in a Patie… DOI 10.1200/po.21.00024↗
- Paper Survival Benefits of Chemotherapy for Patients with Advanced Pancreatic Cancer in A Clinical Real-World Cohort. DOI 10.3390/cancers11091326↗
- Ana Dugic · 1 shared paper, 2026 · strength 0.29
- Miroslav Vujasinović · 1 shared paper, 2026 · strength 0.29
- Christopher Månsson · 1 shared paper, 2025 · strength 0.20
- Nils O. Elander · 1 shared paper, 2025 · strength 0.20
- Bergþór Björnsson · 1 shared paper, 2025 · strength 0.20
- Asif Halimi · 1 shared paper, 2025 · strength 0.20
- Kristina Hasselgren · 1 shared paper, 2025 · strength 0.20
- Heikki I. Huhta · 1 shared paper, 2025 · strength 0.20
- Ernesto Sparrelid · 1 shared paper, 2025 · strength 0.20
- Margareta Heby · 1 shared paper, 2025 · strength 0.20
- Daniel Öhlund · 1 shared paper, 2025 · strength 0.20
- Carlos Fernández Moro · 1 shared paper, 2024 · strength 0.18
- Marco Del Chiaro · 1 shared paper, 2024 · strength 0.18
- Linnéa Malgerud · 1 shared paper, 2024 · strength 0.18
- Raffaella Pozzi Mucelli · 1 shared paper, 2024 · strength 0.18
- Jan‐Erik Frödin · 1 shared paper, 2024 · strength 0.18
- Mikael Björnstedt · 1 shared paper, 2024 · strength 0.18
- Nikolaos Kartalis · 1 shared paper, 2024 · strength 0.18
- Jingru Yu · 1 shared paper, 2019 · strength 0.12
How to reach this person
A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.